Elicio Therapeutics (ELTX) Total Liabilities (2020 - 2026)

Elicio Therapeutics has reported Total Liabilities for 7 years, with the latest figure at $24.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 25.4% year-over-year to $24.1 million; the trailing twelve-month figure through Mar 2026 stood at $24.1 million (up 25.4% YoY), and the FY2025 full-year result was $24.2 million, down 38.65% from the prior year.
• Total Liabilities for Q1 2026 stood at $24.1 million, roughly flat from $24.2 million in the prior quarter.
• The five-year high for Total Liabilities was $57.4 million in Q3 2024, with the low at $2.1 million in Q1 2023.
• Historically, Total Liabilities has averaged $20.8 million across 5 years, with a median of $17.7 million in 2023.
• Annual changes were most pronounced in 2023 — Total Liabilities tumbled 85.05% — and 2024, when it soared 833.37%.
• Elicio Therapeutics' Total Liabilities stood at $13.7 million in 2022, then climbed by 14.72% to $15.8 million in 2023, then jumped by 150.36% to $39.5 million in 2024, then slumped by 38.65% to $24.2 million in 2025, then decreased by 0.41% to $24.1 million in 2026.
• The last three Total Liabilities figures came in at $24.1 million (Q1 2026), $24.2 million (Q4 2025), and $24.5 million (Q3 2025), per Business Quant data.